Richard Nolan Townsend Sells 5,000 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total transaction of $53,250.00. Following the completion of the transaction, the chief executive officer now owns 120,695 shares of the company’s stock, valued at $1,285,401.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, August 12th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $11.53, for a total value of $57,650.00.
• On Wednesday, July 10th, Richard Nolan Townsend sold 26,969 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $16.50, for a total value of $444,988.50.

Lexeo Therapeutics Trading Down 2.0 %

NASDAQ:LXEO opened at $9.67 on Friday. The firm has a market capitalization of $318.58 million and a price-to-earnings ratio of -0.43. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.38 and a quick ratio of 9.38. The business has a fifty day moving average price of $12.21 and a 200-day moving average price of $13.85. Lexeo Therapeutics, Inc. has a one year low of $9.00 and a one year high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, hitting analysts’ consensus estimates of ($0.64). Sell-side analysts forecast that Lexeo Therapeutics, Inc. will post -2.74 EPS for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Several large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in shares of Lexeo Therapeutics in the first quarter worth $75,000. American International Group Inc. purchased a new stake in Lexeo Therapeutics in the 1st quarter worth $79,000. Rhumbline Advisers increased its stake in Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after buying an additional 3,627 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Lexeo Therapeutics by 12.3% in the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock valued at $510,000 after acquiring an additional 3,483 shares in the last quarter. Finally, Cornell University bought a new position in shares of Lexeo Therapeutics in the first quarter worth about $1,980,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on LXEO shares. Chardan Capital reissued a “buy” rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, August 14th. HC Wainwright lowered their price objective on shares of Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Baird R W raised shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Thursday, June 13th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Finally, Robert W. Baird began coverage on Lexeo Therapeutics in a report on Thursday, June 13th. They issued an “outperform” rating and a $28.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Lexeo Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $22.14.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.